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ABSTRACT Coccidioidomycosis is associated with a broad spectrum of illness severity,
ranging from asymptomatic or self-limited pulmonary infection to life-threatening mani-
festations of disseminated disease. Serologic studies before the widespread availability of
antifungals established current understanding of serologic kinetics and dynamics. Chart
histories and complement fixation (CF) titer trends were analyzed for 434 antifungal-
treated coccidioidomycosis patients, who were classified by three infectious disease phy-
sicians as having either pulmonary uncomplicated coccidioidomycosis (PUC) (n  248),
pulmonary chronic coccidioidomycosis (PCC) (n  64), disseminated coccidioidomycosis
(DC) not including meningitis (n  86), or coccidioidal meningitis (CM) (n  36). The
median maximal CF titers were 1:4 for PUC patients, 1:24 for PCC patients, 1:128
for DC patients, and 1:32 for CM patients. Approximately 25.4% of PUC patients,
6.2% of PCC patients, 2.3% of DC patients, and 8.3% of CM patients did not de-
velop detectable titers during the study period. Maximal titers developed a mean
of 31 days (95% confidence interval [CI], 13 to 50 days) after initial serologic pos-
itivity, with no significant differences between groups. Serologic recurrence oc-
curred in 9% of PUC patients, 36% of PCC patients, 50% of DC patients, and 52%
of CM patients. Median titer improvement rates were 91 days/dilution for PUC
patients, 112 days/dilution for PCC patients, 136 days/dilution for DC patients,
and 146 days/dilution for CM patients. Receiver operating characteristic (ROC)
analysis revealed that CF testing retains moderate classification value for dissem-
inated infections (area under the curve [AUC], 0.82 [95% CI, 0.78 to 0.87]) and
complicated infections (AUC, 0.82 [95% CI, 0.77 to 0.86]). A suitable cutoff value
for complicated infections is 1:32. Findings update serologic parameters that
are relevant for clinical assessment of coccidioidomycosis patients in the triazole
era.
KEYWORDS Coccidioides, coccidioidomycosis, complement fixation, dimorphic
fungus, endemic mycoses, serology, valley fever
Coccidioidomycosis is a fungal disease caused by the dimorphic fungi Coccidioidesimmitis and Coccidioides posadasii. These soil-dwelling organisms exist in the
western United States and Central and South America (1, 2). The diagnosis can be
confirmed by microscopic demonstration of the characteristic forms (endosporulating
spherules) in tissue or patient samples or by positive culture results (3). However, the
majority of coccidioidal infections are identified and/or followed serologically by im-
munodiffusion and complement fixation (CF) testing (1). Enzyme immunoassays (EIAs)
are available that can be used to screen for coccidioidomycosis in high-volume settings,
with confirmation by immunodiffusion testing (1, 4). A typical course of infection
involves IgM production to levels detectable by immunodiffusion within 1 to 3 weeks
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of symptom onset, followed shortly thereafter by IgG production (4, 5). The sensitivity
of immunodiffusion, which can be used to detect both IgG and IgM antibodies, varies
with the serum concentration, but the specificity likely exceeds 95% (6, 7). The CF test
detects IgG antibodies to the chitinase antigen and is less sensitive than immunodif-
fusion (4, 7, 8).
The use of CF-based quantification of coccidioidal IgG in the care of coccidioido-
mycosis was described in the 1950s; results are predictive of disease prognosis (9), and
the approach is useful in the evaluation of therapeutic responses to antifungal treat-
ment (10). Despite widespread use of the CF test to monitor coccidioidal IgG antibodies,
no prior study has systematically evaluated IgG antibody kinetics in patients receiving
antifungal therapy. Studies performed in 1955 and 1956, in the preantifungal era,
indicated that 82% of patients developed CF titers within 7 weeks of infection and 91
to 98% of patients with uncomplicated pulmonary infections developed maximal CF
titers of 1:16 (5, 11). In comparison, only 12 to 23% of disseminated cases developed
titers of 1:16. Following this initial observation, patients with titers of 1:16 were
considered by some to warrant additional clinical and radiologic scrutiny for evidence
of disseminated coccidioidomycosis (DC) (4, 7). However, serologic kinetics and dynam-
ics have not been comprehensively described. The present study was designed to
evaluate longitudinal CF titer dynamics in 434 patients who received antifungals for
either pulmonary uncomplicated coccidioidomycosis (PUC), pulmonary chronic coccid-
ioidomycosis (PCC), DC excluding meningitis, or coccidioidal meningitis (CM).
(These data were presented in part at the 2018 Coccidioidomycosis Study Group
Meeting in Flagstaff, AZ.)
MATERIALS AND METHODS
Chart review. Medical records were obtained for 605 coccidioidomycosis patients treated between
2009 and 2014 and were reviewed and adjudicated, according to type of coccidioidal infection, by at
least two infectious disease physicians. A total of 434 patients met the inclusion criteria for this study.
Inclusion criteria included2 positive physician-ordered serologic immunodiffusion tests (more sensitive
than CF and thus a better indicator of infection) performed in the reference laboratory. Exclusion criteria
included pregnancy, breastfeeding, or 3 months postpartum at the time of diagnosis; immunosup-
pressive medications (including systemic corticosteroids, tumor necrosis factor alpha blockers, transplant
medications, cyclophosphamide, azathioprine, methotrexate, or cyclosporine); phenotypic findings sug-
gesting an underlying immunologic disorder (i.e., concurrent Mycobacterium avium complex or other
opportunistic infections in addition to coccidioidomycosis); or HIV positivity. Cases were classified as
either PUC (n  248), with no evidence of coccidioidal relapse during 2 years of observation without
antifungal therapy; PCC (n  64), with continued symptoms and radiographic findings consistent with
active pulmonary infection for 3 months, as described previously (12); DC (n  86), with culture or
histopathologic confirmation of extrathoracic disease; or CM (n  36), with positive coccidioidal
cerebrospinal fluid (CSF) serology in the context of CSF white blood cell (WBC), protein, and/or glucose
changes suggesting infection (European Organization for Research and Treatment of Cancer/Invasive
Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases
Mycoses Study Group definitions [3]) (Table 1). Patients who could not be categorized were excluded. All
patients in this cohort received azole antifungal therapy. All study protocols were reviewed and
approved by the University of California, Davis, institutional review board (protocol 233020-9).
Serologic data. Serum coccidioidal immunodiffusion and CF titer data were collected for each
enrolled patient for all specimens tested through June 2017. All patients had detectable coccidioidal CF
(IgG) and/or coccidioidal precipitin (IgM) confirmed by immunodiffusion at least twice during the
infection course, as well as at least 2 coccidioidal CF tests (not necessarily positive). Immunodiffusion and
CF were performed as described previously (4). Titer analyses involved serum CF data or, when CF yielded
invalid or equivocal results, quantitative immunodiffusion data. References to serologic titer data in this
article refer to CF titer data unless indicated otherwise. Spent coccidioidal culture supernatant, prepared
as described previously, was used as the antigen for immunodiffusion and CF assays (7).
Data analysis. All statistical, mathematical, and graphical analyses were performed in R, using
custom scripts (13). Statistical analyses and comparisons involving titers were performed on log2-
transformed titers; where necessary, results were converted back to titers by calculating 2x, where x is the
log2-transformed titer. Histogram density comparison plots were generated using the R sm package (14).
Receiver operating characteristic (ROC) plots and associated sensitivity, specificity, positive predictive
value (PPV), area under the curve (AUC), confidence interval (CI), and Delong’s significance analyses were
performed using the R pROC package (15). The prevalence of complicated or disseminated disease for
PPV calculations was the prevalence in the study population, which may not reflect proportions that are
epidemiologically observed. Youden’s J statistic was calculated to identify optimal classification titer
thresholds (16).
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Titer trend plots. The irregularity of sample numbers and intervals among patients and groups
required in silico CF titer resampling with 10-day intervals for all patients. Resampling was performed by
assigning CF titers at 10-day intervals (which we found facilitated an optimized granular view of overall
trends) after the initial positive serologic test by replicating the closest previous titer. Titers were
resampled up to a maximum of 5,500 days (15 years). For patients who lacked serologic data of this
duration, titers were linearly imputed using the slope calculated as described below (serologic improve-
ment rate). Each patient’s titer history was synchronized using the date of the initial positive serologic
test (the initial positive test was often an immunodiffusion test, given the relatively increased sensitivity
of immunodiffusion testing, compared with CF) as day 0. Figure 1A presents intragroup average titers at
10-day intervals using these data.
Serologic improvement rates. Titer reduction rates among different types of infections were
determined by calculating titer slopes for each patient using the following formula: m  (Δtime/ΔCF),
where ΔCF refers to the difference in log2-transformed maximal and lowest subsequent minimal CF titers
and Δtime refers to the number of days between the maximal titer and the subsequent minimal titer.
Serologic recurrence detection. Serologic recurrence, defined here as a 4-fold increase (2
dilutions) in CF titer at least 90 days after initial serologic positivity, was bioinformatically detected and
quantified using a custom R-based algorithm that identified local maxima in each patient’s longitudinal
titer history and removed any maxima that did not involve a 4-fold increase from either the previous
titer or an immediately preceding local minimum.
RESULTS
Study population. The study included 434 patients, including 248 with PUC, 64
with PCC, 86 with DC, and 36 with CM (Table 1). The average age at initial diagnosis was
46.9 years (range, 0.87 to 84.2 years) for PUC, 49.2 years (range, 12.3 to 81.1 years) for
PCC, 42.1 years (range, 8.7 to 78.2 years) for DC, and 43.1 years (range, 19.9 to 68.7
years) for CM. All patients in this study received antifungal therapy; all PUC patients
were treated with fluconazole. CF titer data yielded an average of 3.1 years (95% CI, 2.8
to 3.5 years) of serologic data for PUC patients, 4.7 years (95% CI, 3.8 to 5.6 years) of
serologic data for PCC patients, 8.9 years (95% CI, 7.4 to 10.4 years) of serologic data for
DC patients, and 6.5 years (95% CI, 4.9 to 8.1 years) of serologic data for CM patients.
The average number of specimens serologically tested (by both immunodiffusion and
CF) per patient during these periods was 6.3 specimens (95% CI, 5.7 to 6.7 specimens)
for PUC patients, 13.7 specimens (95% CI, 11.7 to 15.6 specimens) for PCC patients, 19.8
specimens (95% CI, 17.3 to 22.3 specimens) for DC patients, and 15.2 specimens (95%
CI, 10.5 to 20 specimens) for CM patients. The median number of days between
serologic tests was 171 days (95% CI, 144 to 198 days) for PUC patients, 117 days (95%
TABLE 1 Study population
Characteristic PUC PCC DC CM
No. of patients 248 64 86 36
No. (%) of patients who developed maximal serum
CF titers of 1:2
185 (74.6) 60 (93.8) 84 (97.7) 33 (91.7)
No. (%) of patients with titers resolved to 1:2
during study period
104 (56.2) 23 (38.3) 27 (32.1) 16 (48.5)
No. of serum specimens tested (mean [95% CI]) 6.3 (5.7–6.7) 13.7 (11.7–15.6)a 19.8 (17.3–22.3)a 15.2 (10.5–20.0)a
Time between tested serum specimens (median
[95% CI]) (days)
171 (144–198) 117 (92–141)a 116 (99–132)a 144 (97–191)
Duration of serologic follow-up monitoring (mean
[95% CI]) (yr)
3.1 (2.8–3.5) 4.7 (3.8–5.6)a 8.9 (7.4–10.4)a 6.5 (4.9–8.1)a
Age (mean [range]) (yr) 46.9 (0.87–84.2) 49.2 (12.3–81.1) 42.1 (8.7–78.2)a 43.1 (19.9–68.7)
Gender (no. [%])
Male 148 (60) 47 (73)b 69 (83)b 29 (81)b
Female 100 (40) 17 (17)b 14 (17)b 7 (19)b
Ethnicity (no. [%])
Asian 5 (2) 1 (2) 3 (4) 1 (3)
African-American 5 (2) 6 (9) 41 (48) 9 (25)
Caucasian 29 (12) 6 (9) 8 (9) 8 (22)
Hispanic 83 (34) 26 (41) 14 (16) 6 (17)
Pacific Islander 0 0 7 (8) 0
Unknown/other 126 (51) 25 (39) 13 (15) 12 (33)
aStudent’s t test, P  0.05, compared with PUC.
bFisher’s exact test P  0.05, compared with PUC.
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CI, 92 to 141 days) for PCC patients, 116 days (95% CI, 99 to 132 days) for DC patients,
and 144 days (95% CI, 97 to 191 days) for CM patients. There were more male patients
than female patients in all groups.
Maximal serum CF titers and trends. The average temporal titer trends for
patients in each group (Fig. 1A) showed that the average patient developed a maximal
CF titer shortly after initial serologic positivity and improved thereafter. Importantly, the
maximal titers shown in Fig. 1A do not reflect the true average maximal titers in each
group, because titers were temporally synchronized to simplify visualization. The
FIG 1 Titer trends and maximal titers. (A) Average titer trend for each group. (B and C) Histogram density plot (B) and boxplot (C) of
maximal titers for each group. The average maximal titers shown in panel A differ from the results calculated for panel C due to temporal
synchronization required for visualization and interindividual variations in the time to maximal titer. Boxes represent the first and third
quartiles. Whiskers represent 1.5 times the interquartile range. *, Student’s t test, P  4.7  106.
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maximal serum CF titer was then determined for each patient (throughout the infection
course), and results were compared in aggregate between groups. Importantly, not all
patients developed a titer detectable by CF. Approximately 25% of PUC patients
(63/248 patients), 6% of PCC patients (4/64 patients), 2% of DC patients (2/86 patients),
and 8% of CM patients (3/36 patients) failed to develop a detectable CF titer during the
study period and were instead diagnosed and monitored by qualitative immunodiffu-
sion, which is more sensitive and specific than CF for coccidioidal antibody detection.
Thus, immunodiffusion remains important for the diagnosis and, in some cases, mon-
itoring of coccidioidomycosis, particularly for patients who fail to develop a detectable
CF titer or whose titer improves to 1:2 (4).
The distribution of maximal titers in each group is shown in Fig. 1B. Notably, PCC
cases and CM cases had broader peak distributions, suggesting a range of disease
severity, while DC and PUC cases had much tighter peak distributions. The median
maximal titers were 1:4 (mean, 1:5 [95% CI, 1:4 to 1:6]; range, 1:2 to 1:512) for PUC
cases, 1:24 (mean, 1:24 [95% CI, 1:15 to 1:39]) for PCC cases, 1:128 (mean, 1:102 [95%
CI, 1:70 to 1:148]) for DC cases, and 1:32 (mean, 1:37 [95% CI, 1:18 to 1:75]) for CM cases
(Fig. 1C). The increased mean titers observed for PCC, DC, and CM patients, compared
with PUC patients, were statistically significant (Student’s t test, P  5  106), further
solidifying the highly significant correlation between CF titers and disease severity.
To contextualize maximal titers observed in this study, CF titer data were extrapo-
lated from published preantifungal studies for comparison (5). Patients with uncom-
plicated disease from the preantifungal era developed a median maximal titer of 1:2
(mean, 1:4 [95% CI, 1:4.2 to 1:4.5]), significantly lower than that of the PUC group
(Student’s t test, P  0.032) but still within the 1-dilution (2-fold) error range of the
method. Further analysis revealed that 83% (207/248 cases) and 94% (233/248 cases) of
PUC cases developed maximal titers of 1:16 and 1:32, respectively (Table 2). In
contrast, 91 to 98% and 97 to 99% of uncomplicated cases in the preantifungal studies
developed titers of 1:16 and 1:32, respectively (5). These findings suggest that
maximal titers of uncomplicated coccidioidomycosis cases are slightly higher in the
antifungal era, compared with the preantifungal era. Meanwhile, 50% (32/248 cases),
20% (17/64 cases), and 42% (15/86 cases) of PCC, DC, and CM cases, respectively,
developed maximal titers of 1:16, largely overlapping with disseminated case titers
from preantifungal studies. This finding suggests that significantly higher titers are
observed among some nondisseminated cases in the antifungal era, which could
complicate classification accuracy of CF for disseminated cases.
Quantitative analysis of CF titers as classifiers of coccidioidomycosis severity.
To begin examination of the extent to which CF titers can differentiate uncomplicated
cases from nonmeningeal disseminated infections, ROC curves comparing DC and PUC
patients were generated (Fig. 2, DC versus PUC comparison). The AUC was 0.903,
indicating that CF can, if other disease manifestations are excluded, fairly reliably
distinguish DC patients from PUC patients. Given the broad overlap of maximal titers
observed among DC, PCC, and CM patients (Fig. 1), this pairwise comparison is clearly
overly simplified but may align with preantifungal-era classification accuracy. Therefore,
to define modern classification accuracy for disseminated (CM and DC) and nondis-
TABLE 2Maximum serum titer associations
Study and titer
No. (%) of cases
PUC PCC DC CM
Current study
16 207 (83) 32 (50) 17 (20) 15 (42)
32 233 (94) 39 (61) 25 (29) 20 (56)
Study by Smith et al. (5)
16 (91–98) NTa (12–23) (41–62)
32 (97–99) NT (27–40) (75–81)
aNT, not tested explicitly.
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seminated (PUC and PCC) cases, cases were grouped accordingly and analyzed by ROC
plot (Fig. 2, disseminated versus nondisseminated comparison). The AUC of the ROC
curve was 0.822 (95% CI, 0.78 to 0.87), significantly (Delong’s test, P  0.0078) lower
than the AUC of 0.903 for the pairwise disseminated disease comparison but still
indicating moderate classification accuracy (17). To determine CF classification accuracy
for complicated versus uncomplicated cases, all non-PUC patients (PCC, DC, and CM
patients) were combined into a single group (complicated) and compared against PUC
patients (Fig. 2, complicated versus PUC comparison). The AUC of this ROC curve was
0.815 (95% CI, 0.77 to 0.86), not significantly different from and nearly superimposing
that for the disseminated versus nondisseminated comparison. To identify classification
accuracy at each possible CF threshold, the sensitivity, specificity, and PPV were
calculated at each titer between 1:2 and 1:1,024 for each relevant comparison. These
data, shown in Table 3, revealed that no cutoff value with perfect sensitivity and
specificity exists. Higher titers are more specific but less sensitive for disseminated and
complicated infections, due to the small numbers of DC, CM, and PCC cases with
relatively low CF titers.
FIG 2 ROC plots. Overlaid ROC plots show the classification accuracy for DC versus PUC cases (AUC, 0.903
[95% CI, 0.86 to 0.94]) (a perfect classifier would have a sensitivity and specificity of 1 along all points and
thus would have an AUC of 1), complicated (COMP) versus uncomplicated cases (AUC, 0.815 [95% CI, 0.77
to 0.86]), and disseminated (DIS) versus nondisseminated (NDIS) cases (AUC, 0.822 [95% CI, 0.78 to 0.87]).
The x axis is reversed and is labeled “specificity,” as opposed to “1  specificity.”
TABLE 3 Sensitivity and specificity at each possible serum CF titer threshold
Titer
threshold
Disseminated vs nondisseminated Complicated vs uncomplicated
Sensitivity
(% [95% CI])
Specificity
(% [95% CI]) PPV (% [95% CI])
Sensitivity
(% [95% CI])
Specificity
(% [95% CI]) PPV (% [95% CI])
1:2 95.9 (91.8–99.2) 21.5 (17.3–26) 32.3 (30.9–33.7) 95.2 (91.9–97.8) 25.4 (20.2–31) 48.9 (47–51)
1:4 95.1 (91–98.4) 30.8 (26–35.9) 35 (33.1–37) 91.9 (88.2–95.7) 35.1 (29–41.5) 51.5 (49–54)
1:8 89.3 (83.6–94.3) 49.4 (43.9–55.1) 40.8 (37.9–44) 83.9 (78.5–89.2) 55.2 (48.8–61.3) 58.4 (54.7–62.2)
1:16a 85.2 (78.7–91) 66.3 (61.2–71.5) 49.8 (45.7–54.4) 75.8 (69.4–81.7) 72.6 (66.9–78.2) 67.4 (62.4–72.3)
1:32b 73.8 (65.6–82) 76.6 (71.8–81.4) 55.4 (49.4–60.9) 65.6 (58.6–72) 83.5 (79–87.5) 74.7 (69.2–80.7)
1:64 63.1 (54.9–71.3) 87.2 (83.3–91) 66 (58.8–73) 54.8 (47.8–61.8) 94 (90.7–96.8) 87.3 (81.6–92.8)
1:128 47.5 (39.3–56.6) 92 (89.1–94.9) 70 (61.5–79) 39.8 (32.8–46.8) 96.4 (94–98.4) 89.3 (82–95.2)
1:256 35.2 (27–43.4) 94.6 (92–97.1) 71.8 (61–82) 29.6 (23.1–36) 98 (96–99.6) 92.1 (84.2–98.2)
1:512 19.7 (13.1–27) 98.1 (96.5–99.4) 80.6 (65.4–93.1) 15.6 (10.8–21) 99.6 (98.8–100) 96.9 (88.4–100)
1:1,024 11.5 (5.7–17.2) 99 (97.8–100) 83.3 (61.5–100) 9.1 (5.4–13.4) 100 (100–100) 100 (100–100)
aOptimal Youden threshold for distinguishing disseminated from nondisseminated infections (J  0.52).
bOptimal Youden threshold for distinguishing complicated from uncomplicated infections (J  0.49).
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To identify CF titer cutoff values with maximal classification performance for dis-
seminated and complicated infections, Youden’s J statistics (16) were calculated at each
titer threshold. Using this method, the best performing CF classification threshold for
disseminated versus nondisseminated disease was 1:16 (J  0.52), with a sensitivity
of 85.2% (95% CI, 78.7 to 91%), a specificity of 66.3% (95% CI, 61.2 to 71.5%), and a PPV
of 49.8% (45.7 to 54.4%), indicating that 50% of patients with titers of 1:16 did not
have disseminated infections. The best performing classification threshold for compli-
cated versus uncomplicated cases was1:32 (J 0.49), with a sensitivity of 65.6% (95%
CI, 58.6 to 72%), a specificity of 83.5 (95% CI, 79 to 87.5%), and a PPV of 74.7 (95% CI,
69.2 to 80.7%). Comparing PPVs between the cutoff values showed that the 1:32
threshold for complicated infections was more specific and reliable than the 1:16
threshold for disseminated disease.
Time to maximal CF titers and serologic recurrences. Initial attempts to deter-
mine the time to maximal titer from the initial serologic positive result suggested that
PCC, DC, and CM cases developed maximal titers significantly later than PUC cases (Fig. 3A).
However, these analyses were revealed to be skewed by numerous outliers in each
group (Fig. 3B). When analyzed individually, high-end outliers appeared to represent
serologic recurrences, or 4-fold (2 dilution) increases in titer (see Fig. S1 in the
supplemental material). Therefore, a titer-scanning algorithm was developed to detect,
to quantify, and to compare serologic recurrences at least 90 days after the initial
serologic positive result. Serologic recurrences were detected in all groups but were
significantly (Student’s t test, P  3  104) more common and frequent among PCC,
DC, and CM patients, compared with PUC patients (Table 4 and Fig. 3C). Only 9% of PUC
patients (22/248 patients) had one or more detectable serologic recurrences, compared
with 36% of PCC patients (23/64 patients) (Fisher’s exact test, P  5.5  107,
compared with PUC patients), 50% of DC patients (43/86 patients) (Fisher’s exact test,
FIG 3 Maximal titer development kinetics. (A and D) Boxplots showing time to maximal titer for each group, including serologic
recurrences (A) and excluding serologic recurrences (D). (B) Histogram density plot of time to maximal titer for each group, showing
numerous outliers in each group, ranging from 102 days to 103 days. Outliers were more abundant for more complicated infections. (C)
Number of recurrences per patient in each group, which contributed to the overestimated time to maximal titers in panel A. Titer data
for boxplot analyses were log10 transformed to account for numerous high-end outliers. Statistical analyses were performed with
untransformed data. *, Student’s t test, P  0.05; **, Student’s t test, P  3  104.
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P  7  1015, compared with PUC patients), and 52% of CM patients (19/36 patients)
(Fisher’s exact test, P  2.7 109, compared with PUC patients). Times to maximal CF
titers were then reanalyzed, excluding the 107 patients with serologic evidence of
recurrence. The resulting analysis of data for 327 patients revealed no significant
difference in times to maximal titers between groups (Fig. 3D). The overall mean time
to maximal titer among these patients was 31 days (95% CI, 13 to 50 days). Seventy-six
percent of patients (248/327 patients) exhibited maximal titers at the initial serologic
diagnosis, and 90% of patients (295/327 patients) developed maximal titers by 50 days
postdiagnosis. The remaining 10% of patients (32/327 patients), who developed max-
imal titers after 50 days, were analyzed further. Sixty-nine percent of those patients
(22/32 patients) developed maximal titers at the first serologic test after the initial
diagnosis, the schedule of which was uncontrollable, given that all tests were physician
ordered. The remaining 10 patients (6 PUC patients, 2 PCC patients, 1 DC patient, and
1 CM patient) all exhibited maximal titers of 1:8 and appeared to undergo very minor
serologic increases at some point, which did not meet algorithmic recurrence criteria.
These data indicate that maximal titers develop usually 30 days, and very rarely 50
days, from initial serologic positivity except in cases of serologic recurrence or thera-
peutic failure.
Serologic improvement rates. Serologic improvement rates were then examined
to help guide patient and clinician expectations of serologic resolution. Among patients
who developed detectable titers, serologic resolution to titers of1:2 was observed for
56.2% of PUC patients (104/185 patients), 38.3% of PCC patients (23/60 patients), 32.1%
of DC patients (27/84 patients), and 48.5% of CM patients (16/33 patients); these
differences were not statistically significant (Table 1). Initial analysis of rates of serologic
improvement from maximal titers suggested extremely prolonged resolution rates (Fig.
4A), although further analysis revealed that the rates were also skewed by high-end
outliers (Fig. 4B). Titer trend analysis of outlier patients indicated that many patients
were serologic “nonimprovers” or failed to improve serologically at an overall rate of at
least 2-fold (1 dilution) per year (Fig. S2). In total, 15% of PUC patients (36/248 patients),
25% of PCC patients (16/64 patients) (Fisher’s exact test, P 0.058, compared with PUC
patients), 31% of DC patients (27/86 patients) (Fisher’s exact test, P 0.0012, compared
with PUC patients), and 25% of CM patients (9/36 patients) (Fisher’s exact test, P 0.14,
compared with PUC patients) were serologic nonimprovers (Table 5). Reanalysis of
serologic improvement rates excluding nonimproving patients revealed that the me-
dian overall improvement rate was 91 days/dilution (mean, 122 days/dilution [95% CI,
107 to 138 days/dilution]) for PUC patients, 112 days/dilution (mean, 131 days/dilution [95%
CI, 102 to 161 days/dilution]) for PCC patients, 136 days/dilution (mean, 156 days/dilution
[95% CI, 129 to 185 days/dilution]) for DC patients, and 146 days/dilution (mean, 168
days/dilution [95% CI, 119 to 216 days/dilution]) for CM patients (Fig. 4C). The only
significant difference was between PUC and DC patients, with the latter exhibiting com-
paratively prolonged titer improvement rates (Student’s t test, P 0.02). Titer improvement
rates of CM patients also appeared prolonged, compared with PUC patients, but this
difference was not statistically significant (Student’s t test, P  0.08). These results indicate
that overall titer improvement rates are variable and slightly prolonged in disseminated
cases. Importantly, serofast-like phenotypes among PUC patients were surprisingly com-
mon and, given the long duration of clinical follow-up monitoring without antifungal
therapy in this study, did not appear to affect clinical outcomes.
TABLE 4 Serologic recurrences
Patient group
No. (%) of patients
PUC PCC DC CM
With no recurrence 226 (91) 41 (64) 43 (50) 17 (47)
With 1 recurrence 22 (9) 23 (36) 43 (50) 19 (52)
Pa 5.5  107 7  1015 2.7  109
aFisher’s exact test, performed pairwise with control group.
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DISCUSSION
This, the first quantitative study of coccidioidomycosis serologic dynamics in the
antifungal era, reveals new insights that could help guide clinical evaluation and
patient management. Physicians often monitor CF titer trends of their patients to help
guide treatment decisions but in recent times have done so without established
modern serologic criteria for comparison.
Preantifungal studies by Smith et al. (5, 9, 11) indicated that only 2.4 to 9.3% of
patients with nondisseminated infections developed maximal titers of 1:16, regard-
less of clinical manifestations (such as pulmonary residuals or pulmonary cavities), while
58 to 65% of patients with disseminated infections developed titers of 1:16. With this
as guidance, CF titers of 1:16 were considered a specific indication of possible
dissemination (7). In the present study, not only did patients with uncomplicated
pulmonary infections develop significantly higher maximal titers (17% of PUC cases
developed titers of 1:16), but also patients with nondisseminated chronic pulmonary
infections developed significantly higher titers that largely overlapped with those of CM
and DC patients. Thus, higher titers are attainable without dissemination in the
antifungal era. Among possible explanations, this could be a related to population
changes (e.g., higher susceptible population density in areas in which the fungus is
FIG 4 Serologic improvement rates. (A and C) Boxplots showing serologic improvement rates (days per 1-titer [2-fold] reduction) for each group, including
serologic nonimprovers (A) and excluding serologic nonimprovers (C). (B) Histogram density plot of serologic improvement rates for each group, indicating that
outlier rates of 365 days/dilution were more abundant in complicated (PCC, DC, and CM) cases. Titer data for boxplot analyses were log10 transformed to
account for numerous high-end outliers. Statistical analyses were performed with untransformed data. *, Student’s t test, P  0.05.
TABLE 5 Serologically nonimproving patients
Patient
group
No. (%) of patients
PUC PCC DC CM
Improving 212 (85) 48 (75) 59 (69) 27 (75)
Nonimproving 36 (15) 16 (25) 27 (31) 9 (25)
Pa 0.058 0.0012 0.14
aFisher’s exact test, performed pairwise with control group.
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endemic) and/or more severe infections (possibly linked to climate change and in-
creases in airborne arthroconidia [18]).
Accordingly, the classification accuracy of CF was reexamined. Results indicate that
the statistically optimal cutoff value for differentiating disseminated cases from non-
disseminated cases remains 1:16 but, due to its poor PPV, has dubious clinical utility. In
the absence of additional diagnostic testing or clinical guidance, CF titers of 1:32 can
somewhat reliably raise caution regarding possible complicated infections, including
disseminated and chronic infections. However, even this cutoff value has a 16.5%
false-positive rate and a 34.4% false-negative rate. Clinical presentation and the pres-
ence of risk factors should ultimately have highest priority in decisions involving patient
management (1). Table 3 provides sensitivity, specificity, and PPV values for dissemi-
nated or complicated infections at each titer threshold and may provide additional
guidance.
This study also identified several additional aspects of coccidioidal serologic dynam-
ics that have not been described previously. First, serologic recurrences were observed
to be surprisingly common (25% [107/434 patients]), even among patients with un-
complicated infections, and were relatively more common among PCC, DC, and CM
patients, compared with PUC patients. Serologic recurrences could hypothetically result
from reexposure, granuloma rupture, transient immunologic changes (e.g., from inter-
current illness), or serologic variability, but additional studies are necessary to identify
conclusive associations. Further investigation will also be necessary to determine
whether such events are clinically relevant or predictable. Second, over 20% of the
study population (88/434 patients) had serologic improvement rates exceeding 365
days/dilution, which far exceeded expectations. Anecdotal reports indicated that some
patients exhibited serofast-like phenotypes even after years without therapy, but these
results indicate that this or related phenomena are much more common than previ-
ously appreciated. Importantly, a serofast-like state was significantly more common
among patients with increased disease severity and, in many cases, may reflect a
host-pathogen equilibrium. For patients with uncomplicated infections, however, all of
whom received fluconazole therapy, this phenomenon may indeed reflect a serofast
state similar to that occasionally observed in syphilis-infected patients (19). Further
studies will be necessary to determine whether these patients are at increased risk of
disease recurrence or if they need to be monitored for additional time.
Finally, this study revealed quantitative, actionable, serologic kinetic data. First, times to
maximal CF titers were similar across all groups, rarely exceeding 50 days from the initial
serologic positive result. Therefore, assuming an incubation period of 10 to 16 days (4) and
2 weeks of diagnostic delay, maximal titers likely develop within 2 to 3 months after the
initial arthroconidia exposure in most cases. Accordingly, if knowledge of a patient’s
maximal initial CF titer is desired, then a reasonable recommendation would be to test
between 1 and 2 months after initial serologic evidence of coccidioidomycosis is obtained.
Second, titer reduction rates were examined and found to range from a median of 3
months/dilution for uncomplicated infections to 4 months/dilution for disseminated
cases. Notably, since overall titer improvement rates were calculated (i.e., time from
maximal titer to subsequent minimum titer), these data may underestimate temporal
variations in resolution rates. For example, titer trends in Fig. 1A suggest temporarily
accelerated titer improvement rates immediately following initial serologic maxima. This
phenomenon is also seen at the individual level in Fig. S1A and D in the supplemental
material. However, the resolution rates described offer clinicians some standard against
which to compare the serologic responses of their patients and could help inform testing
schedules for disease monitoring. For example, a reasonable testing interval to monitor
serologic improvement in uncomplicated pulmonary cases is 3 months.
Several limitations are associated with this study. The retrospective nature of the analysis
precludes precise measurement of titer development, since the date of symptom onset
could not be definitively determined for each patient, and serologic time points were
determined by physician order and thus testing was performed at irregular intervals,
resulting in significant differences in testing frequency and duration between tests, which
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could skew kinetic trends. Other limitations of this study include the following. (i) Chart
review was performed only between 2009 and 2014, and any subsequent clinical changes
that might necessitate case reclassification might not be reflected. (ii) Antifungal drugs and
doses and treatment duration and initiation were not controlled for between groups
(except that all patients received antifungal therapy and all PUC patients received at least
a partial course of fluconazole), which could potentially have implications for disease
manifestation and/or CF titer distributions (20). (iii) Comparisons made with preantifungal-
era studies could be affected by intervening changes in demographics, environment,
climate, and diagnostic reagents. (iv) Only a single reference laboratory was used to acquire
CF titer data; therefore, results may not accurately represent the result interrun and intrarun
variability or consistency observed in other clinical laboratories. In conclusion, this study
provides contemporary assessment of coccidioidomycosis serologic dynamics, revealing
many new aspects of disease serology that may aid clinical evaluation and therapeutic
decision-making in this antifungal era.
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